All In MedTech

FDA Clearance Tracker · P930027

IMMULITE SYSTEMS PSA & THIRD GENERATION PSA REAGENTS

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Sep 15, 1995 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Sep 15, 1995

Approved

Time to decision

766 days

Received Aug 10, 1993. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P930027
Device name
IMMULITE SYSTEMS PSA & THIRD GENERATION PSA REAGENTS
Applicant location
Gwynedd Ll55 4el
Received
Aug 10, 1993
Decided
Sep 15, 1995
Decision
Approved

Device type

Device class
Class III

Every decision under product code MTF

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE COAT-A-COUNT PSA IRMA

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • We could not check whether this was the first decision under its product code.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Siemens Healthcare Diagnostics, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.